MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

Home・Listă Acțiuni・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Închisă

4.03 2.03

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

3.96

Maxim

4.13

Indicatori cheie
By Trading Economics
Venit	466K -27M
Vânzări	2M 15M
Marjă de profit	-178.834
Angajați	141
EBITDA	-2M -29M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+272.34% upside

Statistici piață
By TradingEconomics
Capitalizare de piață	8.1M 237M
Deschiderea anterioară	2
Închiderea anterioară	4.03

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

3.17 / 3.4644 Suport & Rezistență

Voyager Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

14 apr. 2026, 23:36 UTC

Achiziții, Fuziuni, Preluări

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

14 apr. 2026, 23:24 UTC

Acțiuni populare

Stocks to Watch: Gloo, Broadcom, GitLab

14 apr. 2026, 22:42 UTC

Achiziții, Fuziuni, Preluări

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

14 apr. 2026, 21:32 UTC

Principalele dinamici ale pieței

GitLab Shares Rise on Expanded Google Cloud Collaboration

14 apr. 2026, 23:54 UTC

Market Talk

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

14 apr. 2026, 23:34 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

14 apr. 2026, 22:54 UTC

Câștiguri

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

14 apr. 2026, 22:54 UTC

Câștiguri

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

14 apr. 2026, 22:54 UTC

Câștiguri

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

14 apr. 2026, 22:54 UTC

Câștiguri

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

14 apr. 2026, 22:17 UTC

Achiziții, Fuziuni, Preluări

Yancoal Australia: Targets Deal Completion Toward End of 3Q

14 apr. 2026, 22:17 UTC

Achiziții, Fuziuni, Preluări

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

14 apr. 2026, 22:17 UTC

Achiziții, Fuziuni, Preluări

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

14 apr. 2026, 22:16 UTC

Achiziții, Fuziuni, Preluări

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

14 apr. 2026, 22:15 UTC

Achiziții, Fuziuni, Preluări

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

14 apr. 2026, 22:14 UTC

Achiziții, Fuziuni, Preluări

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

14 apr. 2026, 22:13 UTC

Achiziții, Fuziuni, Preluări

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

14 apr. 2026, 22:12 UTC

Achiziții, Fuziuni, Preluări

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

14 apr. 2026, 22:12 UTC

Achiziții, Fuziuni, Preluări

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

14 apr. 2026, 22:10 UTC

Achiziții, Fuziuni, Preluări

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

14 apr. 2026, 20:50 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Basic Materials Roundup: Market Talk

14 apr. 2026, 20:33 UTC

Achiziții, Fuziuni, Preluări

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 apr. 2026, 20:32 UTC

Acțiuni populare

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

14 apr. 2026, 19:59 UTC

Achiziții, Fuziuni, Preluări

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 apr. 2026, 19:38 UTC

Câștiguri

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 apr. 2026, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

14 apr. 2026, 19:21 UTC

Market Talk

Evenimente importante

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

14 apr. 2026, 19:09 UTC

Achiziții, Fuziuni, Preluări

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

14 apr. 2026, 18:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 apr. 2026, 18:30 UTC

Market Talk

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Comparație

Modificare preț

Voyager Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

272.34% sus

Prognoză pe 12 luni

Medie 14.67 USD 272.34%

Maxim 25 USD

Minim 8 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruVoyager Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

8 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 8 analiști care au acordat evaluări ale acțiunilor Voyager Therapeutics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

3.17 / 3.4644Suport & Rezistență

Recent bearish events outweigh bullish events.

All events are bearish.

Date financiare

Despre Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.